Agilent Technologies account plan
Developing scientific solutions
At a glance
Agilent Technologies sells lab instruments, software, services, consumables and CDMO capacity; FY2025 revenue $6,948 million, about 18,200 staff.
Agilent Technologies supplies instruments, software, services and consumables for the whole laboratory workflow, plus a specialty CDMO, to pharma and biopharma, diagnostics and clinical labs, chemicals and advanced materials, environmental, food, and academic and government customers. It sells mainly through a direct sales force, with distributors and e-commerce, and runs R&D and manufacturing in the United States, Europe and Asia Pacific. In FY2025 (year to October 31, 2025) net revenue was $6,948 million, up 7%, and net income $1,303 million; the United States accounted for $2,342 million and China including Hong Kong for $1,224 million. Headcount was about 18,200 at July 31, 2026. Padraig McDonnell has been CEO since May 2024.
Business units
Agilent CrossLab
about 42% of FY2025 revenue ($2,908 million)Services (repair, maintenance, compliance, consulting), mostly vendor-neutral consumables such as GC and LC columns, OpenLab software and lab automation, sold to about 59,700 customers. It is the most profitable segment (32.5% operating margin in FY2025) and grew 6% in Q3 FY2026 to $786 million. Led by Angelica Reimann.
Life Sciences and Diagnostics Markets
about 39% of FY2025 revenue ($2,726 million)Liquid chromatography and LC/MS, cell analysis, pathology, companion diagnostics, genomics and the specialty CDMO, now called Agilent Advanced Therapeutics (oligonucleotide APIs and BIOVECTRA). Revenue grew 11% in FY2025 and 11% in Q3 FY2026 to $746 million, including the Biocare acquisition. Led by Simon May.
Applied Markets
about 19% of FY2025 revenue ($1,314 million)Gas chromatography, GC-MS, atomic and molecular spectroscopy, vacuum technology and remarketed instruments for chemicals and advanced materials, environmental and forensics, food and pharma. Revenue rose 1% in FY2025, then 7% in Q3 FY2026 to $346 million. Led by Mike Zhang.
Strategic priorities
- Ignite transformation
- Ignite, announced in late 2024, started with strategic pricing, procurement and tariff mitigation; pricing delivered about 200 basis points in Q3 FY2026, past the initial target of more than 100 basis points.
- Long-range growth targets
- The long-range plan aims for 5 to 7% core revenue growth a year and double-digit EPS growth.
- Pharma and reshoring
- Management sizes the pharma reshoring opportunity at about $1 billion through 2030 and expects to win at least one third; reshoring orders came from five of the top 10 pharma companies in Q3 FY2026.
- Advanced Therapeutics capacity
- Expanding nucleic acid therapeutics manufacturing in Frederick, Colorado; Train C should generate revenue next spring, with 75% of available FY27 capacity under purchase orders.
- Software, automation and AI
- Building software and informatics, lab automation and a digital-lab ecosystem; an enterprise AI strategy runs with OpenAI and BCG X and an Agilent AI Center of Excellence.
- Instrument replacement and new products
- Riding the LC and GC replacement cycle with launches such as the 9500 triple quad ICP-MS, the 8890B and 8860B GCs and the Altura column family.
Latest results
In Q3 fiscal 2026 (quarter to July 31, 2026) net revenue was $1,878 million, up 8% with no currency impact, and nine-month revenue $5,511 million, also up 8%. All three segments and all regions grew; pharma grew 12% and China 9%. GAAP operating margin rose to 23.6% from 20.7% a year earlier, with IEEPA tariff refunds adding about 1 point, and Q3 net income was $362 million. Agilent raised FY2026 guidance to revenue of $7.49 to $7.51 billion (core growth 5.8% to 6%) and EPS of $6.18 to $6.21, with capex of about $450 million.
Investments and deals
- Biocare acquisition
- Acquired Biocare (BC Midco I) on June 24, 2026 for $950 million net to expand pathology, funded partly by $600 million of 4.90% senior notes due 2032.
- BIOVECTRA acquisition
- Bought BIOVECTRA on September 20, 2024 for $915 million in cash, adding microbial fermentation, bioreagents and highly potent APIs to the CDMO.
- Frederick, Colorado capacity
- Capex was $407 million in FY2025; about $450 million is expected in FY2026, mainly for advanced therapeutics capacity in Frederick, Colorado.
- Restructuring plans
- The FY25 plan now targets about $90 million to $95 million of annual savings; a new FY26 plan carries a $15 million charge and about $30 million to $35 million of annual savings.
- Capital return
- Buybacks of $295 million in the first nine months of FY2026, with about $1,654 million left under the 2024 program, and a quarterly dividend of $0.255 per share.
Challenges and risks
- Tariffs and trade
- Higher tariffs and shipping costs compressed FY2025 margins; IEEPA refund claims are filed but their timing is uncertain, and U.S.-China relations remain a named risk.
- Academic and government spending
- Academia and Government was the only end market to decline in FY2025 ($540 million) and fell to $128 million in Q3 FY2026, with U.S. federal funding a named risk.
- Rising tax rate
- Pillar Two top-up taxes lifted the Q3 FY2026 effective tax rate to 18.5% from 8.2%.
- Competition and regulation
- Agilent competes with Thermo Fisher, Danaher, Waters, Shimadzu and others, and must comply with FDA and EU IVDR rules.
- Inventory and supply
- Inventory days on hand rose to 120 at July 31, 2026 (107 a year earlier) on strategic purchases to mitigate tariff risk and secure supply.
What leadership says
“make no mistake our extraordinary q3 results are no accident nor are they purely a function of improving end markets”
“about 1 billion through 2030, and we expect to at least win one third of that”
“We are not aiming to be a generalist CDMO. We are building a specialized, high-capability business in strategic swim lanes.”
“We have large M&A ambitions. BIOVECTRA is just the beginning.”
Where a supplier can help
- Capacity build-out in Colorado
- The Frederick, Colorado advanced therapeutics expansion and Train C start-up create needs for GMP equipment, engineering, validation and staffing suppliers.
- Integrating Biocare
- The Biocare pathology acquisition calls for integration support in systems, supply chain and commercial operations within Life Sciences and Diagnostics Markets.
- Ignite pricing and procurement
- Ignite's focus on pricing, procurement and tariff mitigation opens doors for sourcing, pricing analytics and supply chain tools that support margin goals.
- AI and digital lab
- The enterprise AI strategy and digital-lab ecosystem point to demand for data, connectivity and automation partners that can show clear impact.
- Reshoring demand
- Pharma reshoring orders give suppliers of lab installation, compliance and service capacity a way to support Agilent's push to win a share of that opportunity.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Agilent Technologies?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended October 31, 2025
- Agilent Technologies is a global leader in life sciences, diagnostics and applied markets, selling instruments, software, services and consumables for the entire laboratory workflow; about 18,100 employees at October 31, 2025 (7,100 Americas, 4,400 Europe, 6,600 Asia Pacific).
- FY2025 (year to October 31, 2025): net revenue $6,948 million, up 7% (no currency impact); BIOVECTRA contributed about 2 percentage points. Net income $1,303 million; operating margin 21.3% (down 2 points); gross margin 52.4%.
- Three segments since a November 2024 reorganisation: Life Sciences and Diagnostics Markets ($2,726 million, +11%), Agilent CrossLab ($2,908 million, +6%, the services/consumables/software engine, 32.5% operating margin) and Applied Markets ($1,314 million, +1%).
- End markets: Pharmaceutical and Biopharmaceutical $2,507 million is the largest, then Chemicals and Advanced Materials $1,561 million, Diagnostics and Clinical $1,029 million; Academia and Government ($540 million) was the only one to decline. United States $2,342 million, China including Hong Kong $1,224 million.
- Higher tariffs and shipping costs, an unfavorable mix (lower-margin specialty CDMO) and higher wages compressed margins; Agilent expects to substantially mitigate the tariff impact during fiscal 2026 through supply chain optimization, targeted pricing and cost efficiency.
- Investment: capex $407 million in FY2025 and about $500 million planned for FY2026, mainly to expand nucleic acid therapeutics manufacturing capacity in Frederick, Colorado; BIOVECTRA was bought in September 2024 for $915 million.
- Capital return: $425 million of buybacks and $282 million of dividends in FY2025; about $1.9 billion left under the 2024 repurchase program. FY25 restructuring plan: $81 million charge, $75 million to $80 million of expected annual savings.
- Leadership: Padraig McDonnell CEO since May 2024; Adam Elinoff CFO since November 2025 (ex-Amgen); segment presidents Simon May (LDM), Angelica Reimann (CrossLab), Mike Zhang (Applied Markets); Jonah Kirkwood Chief Commercial Officer.
- Key risks named: customers' capital spending and government funding (U.S. federal funding under a continuing resolution), tariffs and U.S.-China trade, FDA and EU IVDR regulation, acquisitions integration, and competition from Thermo Fisher, Danaher, Waters, Shimadzu and others.
- Form 10-Q for the quarter ended July 31, 2026 (Q3 fiscal 2026)
- Q3 fiscal 2026 (quarter to July 31, 2026): net revenue $1,878 million, up 8% (no currency impact); nine months $5,511 million, up 8% (2 points favorable currency). Growth came from all segments and all regions.
- Q3 income from operations $444 million (+23%), operating margin 23.6% (20.7% a year earlier), gross margin 55.5%; tariff refunds under IEEPA contributed about 1 point of operating margin in the quarter. Q3 net income $362 million.
- Segments in Q3: Life Sciences and Diagnostics Markets $746 million (+11%), Agilent CrossLab $786 million (+6%, operating margin 34.3%), Applied Markets $346 million (+7%, operating margin 24.9%).
- Q3 end markets: Pharmaceutical and Biotechnology $707 million (from $629 million), Chemicals and Advanced Materials $430 million, Diagnostics and Clinical $284 million; Academia and Government fell to $128 million.
- Acquired Biocare (BC Midco I) on June 24, 2026 for $950 million net, expanding the pathology portfolio; funded partly by $600 million of 4.90% senior notes due 2032.
- The specialty CDMO was renamed Agilent Advanced Therapeutics; capex of about $450 million is expected for the year, mainly for advanced therapeutics capacity in Frederick, Colorado.
- New FY26 restructuring plan to optimize the management structure: $15 million charge, about $30 million to $35 million of annual savings; the FY25 plan's expected savings rose to about $90 million to $95 million.
- Customer capital budget availability "has largely normalized"; tariffs and the Middle East conflict remain dynamic but their cost impact was mitigated. Headcount about 18,200.
- Agilent Q3 fiscal 2026 earnings call transcript
- Q3 FY2026 revenue $1.88 billion, core growth 7.3%, 140 basis points above the top of guidance; operating margin 27.2% excluding a $20 million tariff-refund benefit (28.3% including it); EPS $1.56 ex-refund, up 14%.
- Pharma grew 12% (9% excluding CDMO); the Advanced Therapeutics division (NASD and BIOVECTRA) grew nearly 30%; GLP-1 business more than 70% growth; China grew 9% against a flat expectation.
- FY2026 guidance raised: revenue $7.49 to $7.51 billion, core growth 5.8% to 6%; EPS $6.18 to $6.21 ($6.12 to $6.15 ex-refund, 10% growth at the midpoint); capex about $450 million.
- Ignite operating system: strategic pricing delivered about 200 basis points in Q3, past the initial full-year target of more than 100 basis points; AI partnership with OpenAI and BCG X and an Agilent AI Center of Excellence.
- Pharma reshoring: opportunity sized at about $1 billion through 2030, of which Agilent expects to win at least one third; reshoring orders from five of the top 10 pharma companies in Q3; revenue from fiscal 2027.
- Product launches: 9500 triple quad ICP-MS (funnel above $60 million), 8890B and 8860B GCs (orders more than 2x expectations), Altura columns; Train C CDMO capacity to start revenue next spring, with 75% of FY27 available capacity under POs.
- Semiconductor is about 3% to 4% of Agilent revenue; Biocare contributed $10 million in Q3 and about $23 million is expected in Q4.
- Igniting Customer-Centric Growth: A Conversation With Padraig McDonnell Of Agilent Technologies
- Sponsored Asian Scientist feature (August 2025) in which CEO Padraig McDonnell explains the Ignite transformation and Singapore's role for Agilent.
- Ignite is "a company-wide transformation designed to help us scale more effectively and serve customers better", with a strategy "centered on markets and customers, not just products".
- Long-range plan: 5 to 7% core revenue growth a year and double-digit EPS growth; Ignite aims to simplify global processes, reduce complexity and build a more agile value chain.
- Customer promise: shorter lead times, consistency and quality, faster product launches and co-innovation (e.g. PFAS analysis, biopharma workflows).
- Singapore: over 600 scientists, engineers and other staff and a 172,000 square foot facility; S$85 million invested in 2017; S$38 million translational R&D hub with NUS Medicine and NUH launched in 2019.
- Digital lab: AI-driven insights across data, instruments, lab environment and enterprise; four smart factories recognized by the World Economic Forum.
- Five-year vision: more customer-centric, invest in innovation organically and through M&A, expand into high-growth adjacencies, more automation and software.
- Agilent Technologies Interview - US Life Sciences 2025 (GBR)
- Interview of CEO Padraig McDonnell for the GBR "US Life Sciences 2025" report, on Agilent's strategy shift, innovation, biopharma/CDMO and AI.
- Strategy built on four areas: portfolio expansion and innovation, high-growth segments, lab productivity, and software and informatics; enablers include a unified commercial organization, a digital ecosystem and the IGNITE transformation, "the biggest change in 25 years".
- Innovation: the Infinity Tree LC platform boosts lab productivity by 10-20%; collaboration with ABB Robotics on automated labs; R&D shifting to asymmetric investments in the highest-growth areas.
- CDMO: US$750 million invested in oligonucleotide manufacturing in Colorado, then the US$1 billion BIOVECTRA acquisition; "We are not aiming to be a generalist CDMO."
- Emerging areas: cell and gene therapy, large molecules, proteomics and spatial biology.
- AI: two manufacturing sites won World Economic Forum Global Lighthouse Awards; SixSense acquisition enables predictive maintenance; "The key is focus".
- M&A: "We have large M&A ambitions. BIOVECTRA is just the beginning."
Questions about Agilent Technologies
What does Agilent Technologies do?
Agilent sells laboratory instruments, software, services and consumables, and runs a specialty CDMO, for pharma, diagnostics, chemicals, environmental, food and academic labs. It is organised in three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.
What is Agilent's revenue?
Net revenue was $6,948 million in FY2025 (year to October 31, 2025), up 7%. For FY2026 Agilent guides to $7.49 to $7.51 billion.
How many employees does Agilent have?
About 18,200 at July 31, 2026, up from about 18,100 at October 31, 2025, mainly due to the Biocare acquisition.
Who leads Agilent Technologies?
Padraig McDonnell has been President and CEO since May 2024; Adam Elinoff has been CFO since November 2025.
What is Agilent's strategy?
Agilent runs the Ignite transformation, targets 5 to 7% core revenue growth a year and double-digit EPS growth, and invests in advanced therapeutics capacity, pathology, software and AI, and M&A.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)